Non-squamous cell lung cancer
Conditions
Interventions
Single group:Carrizumab+ thalidomide + Pemetrexed + carboplatin
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with age >= 18 years, regardless of gender; 2. Patients with non-small cell lung cancer with advanced non squamous cell carcinoma confirmed by histopathology or cytology; 3. According to RECIST 1.1 standard, subjects must have measurable target lesions that have passed CT or MRI examination; 4. When the patients are enrolled, the WHO / ECoG score was 0 or 1; 5. Life expectancy >= 3 months; 6. Patients sign informed consent and voluntarily joined the study; 7. For patients without severe liver and kidney injury, the functional level of organs must meet the following requirements: ANC >= 1.5 x 10^9 / L; PLT >= 90 x 10^9 / L; HB >= 90 g / L; TBIL = 50 ml / min (Cockcroft Gault formula); LVEF >= 50%; QTCF corrected by fridericia method < 450 ms, female< 470 msINR <= 1.5 x ULN, ACTT <= 1.5 x ULN.
Exclusion criteria
Exclusion criteria: 1. Patients who have received systemic chemotherapy for advanced (metastatic) diseases; 2. There is evidence that neoadjuvant chemotherapy or adjuvant cytotoxic chemotherapy (or both) is completed Patients with disease progression within 6 months after radiotherapy; 3. Patients with allergic or hypersensitive constitution and patients with autoimmune diseases; 4. Patients with third space effusion that cannot be controlled by drainage or other methods (e.g., massive pleural effusion) And ascites); 5. Patients who have been treated with steroids for more than 50 days or need to use steroids for a long time; 6. Patients with uncontrolled symptomatic brain metastases or mental disorders who can not correctly express subjective symptoms; 7. Patients receiving any other anti-tumor treatment at the same time, including anti-tumor Chinese patent medicine and immune preparation; 8. In patients with non swallowing, chronic diarrhea and intestinal obstruction, there are many kinds of drugs that affect the drug taking and absorption factor; 9. Patients with other malignant tumors within 5 years before enrollment were treated with radical therapy Cervical carcinoma in situ or skin squamous or basal cell carcinoma was excluded; 10. Pregnant and lactating women who have fertility but refuse to take contraceptive measures; 11. Patients with severe heart disease or history, including: documented congestive heart failure History, high-risk uncontrollable arrhythmia, angina pectoris requiring drug treatment, clinically confirmed heart valve disease, history of severe myocardial infarction and refractory hypertension; 12. Patients who have received allogeneic tissue / solid organ transplantation; 13. According to the judgment of the researcher, there are accompanying diseases (such as uncontrolled hypertension, diabetes, thyroid disease, etc.) that seriously endanger the safety of patients or affect patients to complete the study; 14. Other cases not suitable for inclusion in the study were determined by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactHan Zhengxiang
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed